Pharma & Biotech Global Week in Review 21 July 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Human rights groups slam Special 301 Report (ArsTechnica) (Michael Geist)

European Commission reports on patent settlement agreements (IP Whiteboard)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Hopes fading for concluding biodiversity access and benefit sharing negotiations? (IP Watch)

EU: European Commission reports on patent settlement agreements (IP Whiteboard)

EU: Patenting tomatoes and broccoli – EPO EBA to consider patentability of biotechnological enhanced breeding methods – G 2/07, G 1/08 (IPEG)

EU/India: Purpose-bound patent protection and lessons for India by Dr Rca Godbole – Monsanto (Spicy IP)

India: Patent grant dates and serial oppositions: A timely clarification: Snehalatha vs UOI and others (Spicy IP)

Ireland fee hike on SPC’s: your chance to comment (The SPC blog)

US: Human rights groups slam Special 301 Report (ArsTechnica) (Michael Geist)

US: Plaintiffs begin appellate fight over gene patents: Association for Molecular Pathology v. USPTO (Inventive Step)

US: Appellees move for recusal of Chief Judge Rader in appeal: Association for Molecular Pathology v. USPTO (Patent Docs)

US: Huffington Post provides latest anti-gene patenting soapbox (Patent Docs)

US: Facts, perhaps the antidote to the anti-gene patenting plague (Patent Docs)

US: Journal examines effects of patent reform on medical innovation (Patent Docs)

 

Products

Cetuximab and Irinotecan – UK: EWHC (Pat) dismisses Yeda’s appeal of UKIPO refusal of two SPC applications relating to a combination treatment for cancer (EPLAW)

Diacereine – France: Novelty of patent over pharmaceutical preparation already disclosed but claimed with higher purity level of active ingredient: Laboratoires Negma v. Biogaran and Laboratoires Medidom (EPLAW)

Fortical (Calcitonin) – US: Unigene secures ruling of infringement against Apotex in Fortical patent suit (Patent Docs)

Levaquin (Levofloxacin) – US: Federal Circuit denies rehearing petition in Levaquin Patent Term Extension case: Ortho-McNeil Pharmaceutical, Inc. v. Lupin Pharmaceuticals, Inc (FDA Law Blog)

Olux (Clobetasol) – Perrigo confirms patent challenge for Colobetasol propionate emulsion foam (GenericsWeb)

Prandin (Repaglinide) – US: Actavis, Sandoz bring inequitable conduct counterclaims against Novo Nordisk in Prandin suit (Patent Docs)

Protonix (Pantoprazole) – US: District Court New Jersey denies Teva’s motion to overturn jury verdict finding the patent in suit not invalid in Protonix litigation (SmartBrief) (GenericsWeb)

Ranexa (Ranolazine) – US: Gilead files patent infringement lawsuit against Lupin based on ANDA (GenericsWeb)

Tarceva (Erlotinib) – India: Roche-Natco to be heard daily from June 27 (Spicy IP)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: